Skip to content
Facebook Instagram Linkedin

LifeScienceHistory.com

History made daily

  • Home
  • DirectoryExpand
    • General Company Directory
    • CRO Directory
    • CMO Directory
    • Genealogy on Demand
  • CareersExpand
    • Find Your Job
    • Advertise Your Life Science Jobs
  • News and History
  • Cartoons
  • Small World
  • Earth is a RockExpand
    • Earth is a Rock
    • Earth is a Rock Lyrics
    • Earth is a Rock Lyrics Defined
LifeScienceHistory.com
History made daily
Home / RNA - Page 9

RNA

Moderna announced FDA authorization of Moderna COVID-19 vaccine in U.S.
Biotechnology | COVID-19 | FDA | Infectious Disease | Vaccine

Moderna announced FDA authorization of Moderna COVID-19 vaccine in U.S.

On Dec. 18, 2020, Moderna announced that the U.S. Food and Drug Administration (FDA) had authorized the emergency…

Read More Moderna announced FDA authorization of Moderna COVID-19 vaccine in U.S.Continue

XPhyto completed successful SARS-COV-2 RT-PCR diagnostic testk kit validation
COVID-19 | Life Science History

XPhyto completed successful SARS-COV-2 RT-PCR diagnostic testk kit validation

On Dec. 17, 2020, XPhyto Therapeutics and 3a-diagnostics announced the successful validation of their point-of-care SARS-CoV-2 (COVID-19) RT-PCR…

Read More XPhyto completed successful SARS-COV-2 RT-PCR diagnostic testk kit validationContinue

Moderna received FDA Advisory Committee vote supporting EUA for vaccine against COVID-19 in the U.S.
Biotechnology | COVID-19 | FDA | Vaccine

Moderna received FDA Advisory Committee vote supporting EUA for vaccine against COVID-19 in the U.S.

On Dec. 17, 2020, Moderna confirmed that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological…

Read More Moderna received FDA Advisory Committee vote supporting EUA for vaccine against COVID-19 in the U.S.Continue

BioNTech and Fosun Pharma to supply China with mRNA-based COVID-19 vaccine
COVID-19 | Life Science History | Vaccine

BioNTech and Fosun Pharma to supply China with mRNA-based COVID-19 vaccine

On Dec. 16, 2020, BioNTech and Shanghai Fosun Pharmaceutical announced an agreement to supply Mainland China with an…

Read More BioNTech and Fosun Pharma to supply China with mRNA-based COVID-19 vaccineContinue

CureVac commenced global pivotal phase 2b/3 trial for COVID-19 vaccine candidate, CVnCoV
COVID-19 | Life Science History | Vaccine

CureVac commenced global pivotal phase 2b/3 trial for COVID-19 vaccine candidate, CVnCoV

On Dec. 14, 2020, CureVac announced that it had enrolled the first participant in the pivotal Phase 2b/3…

Read More CureVac commenced global pivotal phase 2b/3 trial for COVID-19 vaccine candidate, CVnCoVContinue

Moderna confirmed supply agreement to supply Singapore with mRNA vaccine against COVID-19
Biotechnology | COVID-19 | Infectious Disease | Vaccine

Moderna confirmed supply agreement to supply Singapore with mRNA vaccine against COVID-19

On Dec. 14, 2020, Moderna confirmed that the Company had concluded an agreement with the Ministry of Health…

Read More Moderna confirmed supply agreement to supply Singapore with mRNA vaccine against COVID-19Continue

U.S. Government exercised 1st option for additional 100 million doses of Moderna’s COVID-19 vaccine
Biotechnology | COVID-19 | Infectious Disease | Vaccine

U.S. Government exercised 1st option for additional 100 million doses of Moderna’s COVID-19 vaccine

On Dec. 11, 2020, Moderna announced that the U.S. government has exercised its option to purchase an additional…

Read More U.S. Government exercised 1st option for additional 100 million doses of Moderna’s COVID-19 vaccineContinue

Roche partnered with Moderna to include SARS-CoV-2 antibody test in ongoing COVID-19 vaccine trials
Biotechnology | FDA | Infectious Disease | Vaccine

Roche partnered with Moderna to include SARS-CoV-2 antibody test in ongoing COVID-19 vaccine trials

On Dec. 10, 2020, Roche announced a partnership with Moderna to utilise the Elecsys Anti-SARS-CoV-2 S antibody test…

Read More Roche partnered with Moderna to include SARS-CoV-2 antibody test in ongoing COVID-19 vaccine trialsContinue

Moderna announced first participants dosed in phase 2/3 study of COVID-19 vaccine candidate in adolescents
Biotechnology | COVID-19 | Infectious Disease | Vaccine

Moderna announced first participants dosed in phase 2/3 study of COVID-19 vaccine candidate in adolescents

On Dec. 10, 2020, Moderna announced that the first adolescent participants had been dosed in the Phase 2/3…

Read More Moderna announced first participants dosed in phase 2/3 study of COVID-19 vaccine candidate in adolescentsContinue

Pfizer and BioNTech received FDA Advisory Committee vote supporting EUA for COVID-19 vaccine in the US
COVID-19 | FDA | Life Science History

Pfizer and BioNTech received FDA Advisory Committee vote supporting EUA for COVID-19 vaccine in the US

On Dec. 10, 2020, Pfizer and BioNTech announced that the FDA Vaccines and Related Biological Products Advisory Committee…

Read More Pfizer and BioNTech received FDA Advisory Committee vote supporting EUA for COVID-19 vaccine in the USContinue

Roche partnered with Moderna to include SARS-CoV-2 antibody test in ongoing COVID-19 vaccine trials
Biotechnology | FDA | Infectious Disease | Vaccine

Roche partnered with Moderna to include SARS-CoV-2 antibody test in ongoing COVID-19 vaccine trials

On Dec. 9, 2020, Roche announced a partnership with Moderna to utilise the Elecsys Anti-SARS-CoV-2 S antibody test…

Read More Roche partnered with Moderna to include SARS-CoV-2 antibody test in ongoing COVID-19 vaccine trialsContinue

Switzerland exercised increased option for 7.5 million doses of mRNA vaccine against COVID-19 (mRNA-1273)
Biotechnology | COVID-19 | Infectious Disease | Vaccine

Switzerland exercised increased option for 7.5 million doses of mRNA vaccine against COVID-19 (mRNA-1273)

On Dec. 8, 2020, Moderna announced the Swiss Federal Government had increased its confirmed order commitment from 4.5…

Read More Switzerland exercised increased option for 7.5 million doses of mRNA vaccine against COVID-19 (mRNA-1273)Continue

Canada exercised increased option for total of 40 million doses of mRNA vaccine candidate against COVID-19
Biotechnology | COVID-19 | Infectious Disease | Vaccine

Canada exercised increased option for total of 40 million doses of mRNA vaccine candidate against COVID-19

On Dec. 7, 2020, Moderna announced that the Canadian Government had increased its confirmed order commitment by 20…

Read More Canada exercised increased option for total of 40 million doses of mRNA vaccine candidate against COVID-19Continue

Moderna updated on clinical development and production of Its COVID-19 vaccine candidate
Biotechnology | COVID-19 | Infectious Disease | NIH | Vaccine

Moderna updated on clinical development and production of Its COVID-19 vaccine candidate

On Dec. 3, 2020, Moderna announced in a letter to the editor published in the New England Journal…

Read More Moderna updated on clinical development and production of Its COVID-19 vaccine candidateContinue

Pfizer and BioNTech achieved first authorization in the world for a vaccine to combat COVID-19
COVID-19 | Life Science History | Vaccine

Pfizer and BioNTech achieved first authorization in the world for a vaccine to combat COVID-19

On Dec. 2, 2020, Pfizer and BioNTech announced that the Medicines & Healthcare Products Regulatory Agency (MHRA) in…

Read More Pfizer and BioNTech achieved first authorization in the world for a vaccine to combat COVID-19Continue

Pfizer and BioNTech submitted application for Conditional Marketing Authorization for COVID-19 vaccine
COVID-19 | Life Science History | Vaccine

Pfizer and BioNTech submitted application for Conditional Marketing Authorization for COVID-19 vaccine

On Dec. 1, 2020, Pfizer and BioNTech announced they had submitted on Nov. 30, 2020, a formal Application…

Read More Pfizer and BioNTech submitted application for Conditional Marketing Authorization for COVID-19 vaccineContinue

Moderna announced primary efficacy analysis in phase 3 COVE study for COVID-19 vaccine candidate
Biotechnology | Diagnostics | FDA | Infectious Disease | Vaccine

Moderna announced primary efficacy analysis in phase 3 COVE study for COVID-19 vaccine candidate

On Nov. 30, 2020, Moderna announced that the primary efficacy analysis of the Phase 3 study of mRNA-1273…

Read More Moderna announced primary efficacy analysis in phase 3 COVE study for COVID-19 vaccine candidateContinue

Moderna amended supply agreement with UK Government for 2 million doses of mRNA COVID-19 vaccine
Biotechnology | COVID-19 | Infectious Disease | Vaccine

Moderna amended supply agreement with UK Government for 2 million doses of mRNA COVID-19 vaccine

On Nov. 29, 2020, Moderna announced a supply agreement with the United Kingdom (UK) government for an additional…

Read More Moderna amended supply agreement with UK Government for 2 million doses of mRNA COVID-19 vaccineContinue

Moderna announced EC approval of purchase agreement for 80 million doses of mRNA COVID-19 vaccine
Biotechnology | COVID-19 | Infectious Disease | Vaccine

Moderna announced EC approval of purchase agreement for 80 million doses of mRNA COVID-19 vaccine

On Nov. 25, 2020, Moderna announced that the European Commission (EC) has approved an agreement to secure 80…

Read More Moderna announced EC approval of purchase agreement for 80 million doses of mRNA COVID-19 vaccineContinue

BioNTech and Fosun Pharma announced start of phase 2 clinical trial of mRNA COVID-19 vaccine in China
COVID-19 | Life Science History | Vaccine

BioNTech and Fosun Pharma announced start of phase 2 clinical trial of mRNA COVID-19 vaccine in China

On Nov. 25, 2020, BioNTech and Shanghai Fosun Pharmaceutica jointly announced that their lead mRNA COVID-19 vaccine candidate…

Read More BioNTech and Fosun Pharma announced start of phase 2 clinical trial of mRNA COVID-19 vaccine in ChinaContinue

Pfizer and BioNTech to submit Emergency Use Authorization Request to the FDA for COVID-19 vaccine
FDA | Life Science History

Pfizer and BioNTech to submit Emergency Use Authorization Request to the FDA for COVID-19 vaccine

On Nov. 20, 2020, Pfizer and BioNTech announced they submitted a request to the Food and Drug Administration…

Read More Pfizer and BioNTech to submit Emergency Use Authorization Request to the FDA for COVID-19 vaccineContinue

Pfizer and BioNTech announced phase 3 study of COVID-19 vaccine candidate met all efficacy endpoints
COVID-19 | Life Science History | Vaccine

Pfizer and BioNTech announced phase 3 study of COVID-19 vaccine candidate met all efficacy endpoints

On Nov. 18, 2020, Pfizer and BioNTech announced that, after conducting the final efficacy analysis in their ongoing…

Read More Pfizer and BioNTech announced phase 3 study of COVID-19 vaccine candidate met all efficacy endpointsContinue

Moderna announced supply agreement with UK Government to supply mRNA vaccine against COVID-19
COVID-19 | Infectious Disease | Vaccine

Moderna announced supply agreement with UK Government to supply mRNA vaccine against COVID-19

On Nov. 17, 2020, Moderna announced a supply agreement with the government of the United Kingdom (UK) to…

Read More Moderna announced supply agreement with UK Government to supply mRNA vaccine against COVID-19Continue

Moderna announced longer shelf life for its COVID-19 vaccine candidate at refrigerated temperatures
Biotechnology | COVID-19 | Infectious Disease | Vaccine

Moderna announced longer shelf life for its COVID-19 vaccine candidate at refrigerated temperatures

On Nov. 16, 2020, Moderna announced new data showing that mRNA-1273, its COVID-19 vaccine candidate, remained stable at…

Read More Moderna announced longer shelf life for its COVID-19 vaccine candidate at refrigerated temperaturesContinue

BioNTech and Fosun Pharma approved to commence COVID-19 vaccine candidate BNT162b2 trial in China
Life Science History | Vaccine

BioNTech and Fosun Pharma approved to commence COVID-19 vaccine candidate BNT162b2 trial in China

On Nov. 16, 2020, BioNTech and Shanghai Fosun Pharmaceutica announced that the China National Medical Products Administration had…

Read More BioNTech and Fosun Pharma approved to commence COVID-19 vaccine candidate BNT162b2 trial in ChinaContinue

European Medicines Agency began rolling review of Moderna’s mRNA vaccine candidate against COVID-19
Biotechnology | COVID-19 | Infectious Disease | Life Science History | Vaccine

European Medicines Agency began rolling review of Moderna’s mRNA vaccine candidate against COVID-19

On Nov. 16, 2020, Moderna announced that the European Medicines Agency (EMA) human medicines committee (CHMP) had started…

Read More European Medicines Agency began rolling review of Moderna’s mRNA vaccine candidate against COVID-19Continue

Moderna’s COVID-19 vaccine candidate met primary endpoint in first interim analysis of phase 3 COVE study
Biotechnology | COVID-19 | Infectious Disease | Life Science History | NIH | Vaccine

Moderna’s COVID-19 vaccine candidate met primary endpoint in first interim analysis of phase 3 COVE study

On Nov. 15, 2020, an independent data and safety monitoring board (DSMB) overseeing the Phase 3 trial of…

Read More Moderna’s COVID-19 vaccine candidate met primary endpoint in first interim analysis of phase 3 COVE studyContinue

Swissmedic began rolling review of Moderna’s mRNA vaccine against COVID-19
Biotechnology | COVID-19 | Infectious Disease | Therapeutics | Vaccine

Swissmedic began rolling review of Moderna’s mRNA vaccine against COVID-19

On Nov. 13, 2020, Moderna announced that Swissmedic had started a rolling review of mRNA-1273, the Company’s vaccine…

Read More Swissmedic began rolling review of Moderna’s mRNA vaccine against COVID-19Continue

CureVac’s COVID-19 vaccine candidate, CVnCoV, suitable for standard fridge temperature logistics
Biotechnology | COVID-19 | Vaccine

CureVac’s COVID-19 vaccine candidate, CVnCoV, suitable for standard fridge temperature logistics

On Nov. 12, 2020, CureVac announced that its mRNA-based COVID-19 vaccine candidate, CVnCoV, remained stable and within defined…

Read More CureVac’s COVID-19 vaccine candidate, CVnCoV, suitable for standard fridge temperature logisticsContinue

Moderna completed case accrual for first planned interim analysis of mRNA vaccine against COVID-19
Biotechnology | COVID-19 | Infectious Disease | NIH | Vaccine

Moderna completed case accrual for first planned interim analysis of mRNA vaccine against COVID-19

On Nov. 11, 2020, Moderna announced that it had completed case accrual for the first interim analysis of…

Read More Moderna completed case accrual for first planned interim analysis of mRNA vaccine against COVID-19Continue

Page navigation

Previous PagePrevious 1 … 7 8 9 10 11 … 14 Next PageNext
  • Categories
  • Timeline
  • Agriculture
  • Artificial Intelligence
  • Biology
  • Biotechnology
  • Cartoons – Historical
  • Cartoons – Original
  • CDC
  • CDMO
  • Chemical
  • Cloning
  • CMO
  • COVID-19
  • CRISPR
  • CRO
  • Cryogenic
  • Dentistry
  • Diagnostics
  • Disease
  • Energy
  • Environmental
  • EPA
  • FDA
  • Forestry
  • Genomics
  • HIV
  • Infectious Disease
  • Influenza
  • IRB
  • Life Science History
  • Marine Science
  • Materials
  • Measles
  • Medical Device
  • Medicine
  • Nanotechnology
  • Neurology
  • NIH
  • Non-Profit Research
  • Nutraceuticals
  • Oncology
  • Ophthalmogy
  • Organ Transplant
  • Orthopedic
  • Other
  • Pharmaceutical
  • Plague
  • Polio
  • Prehistory
  • Radiology
  • Rare Disease
  • Stem Cell
  • Therapeutics
  • U.S. Congress
  • Uncategorized
  • USDA
  • Vaccine
  • Veterinary
  • WHO
  • Women's Health
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
  • 2009
  • 2008
  • 2007
  • 2006
  • 2005
  • 2004
  • 2003
  • 2002
  • 2001
  • 2000
  • 1999
  • 1998
  • 1997
  • 1996
  • 1995
  • 1994
  • 1993
  • 1992
  • 1991
  • 1990
  • 1989
  • 1988
  • 1987
  • 1986
  • 1985
  • 1984
  • 1983
  • 1982
  • 1981
  • 1980
  • 1979
  • 1978
  • 1977
  • 1976
  • 1975
  • 1974
  • 1973
  • 1972
  • 1971
  • 1970
  • 1969
  • 1968
  • 1967
  • 1966
  • 1965
  • 1964
  • 1963
  • 1962
  • 1961
  • 1960
  • 1959
  • 1958
  • 1957
  • 1956
  • 1955
  • 1954
  • 1953
  • 1952
  • 1951
  • 1950
  • 1949
  • 1948
  • 1947
  • 1946
  • 1945
  • 1944
  • 1943
  • 1942
  • 1941
  • 1940
  • 1939
  • 1938
  • 1937
  • 1936
  • 1935
  • 1934
  • 1933
  • 1932
  • 1931
  • 1930
  • 1929
  • 1928
  • 1927
  • 1926
  • 1925
  • 1924
  • 1923
  • 1922
  • 1921
  • 1920
  • 1919
  • 1918
  • 1917
  • 1916
  • 1915
  • 1914
  • 1913
  • 1912
  • 1911
  • 1910
  • 1909
  • 1908
  • 1907
  • 1906
  • 1905
  • 1904
  • 1903
  • 1902
  • 1901
  • 1900
  • 1899
  • 1898
  • 1897
  • 1896
  • 1895
  • 1894
  • 1893
  • 1892
  • 1891
  • 1890
  • 1889
  • 1888
  • 1887
  • 1886
  • 1885
  • 1884
  • 1883
  • 1882
  • 1881
  • 1880
  • 1879
  • 1878
  • 1877
  • 1876
  • 1875
  • 1874
  • 1873
  • 1872
  • 1871
  • 1870
  • 1869
  • 1868
  • 1867
  • 1866
  • 1865
  • 1864
  • 1863
  • 1862
  • 1861
  • 1860
  • 1859
  • 1858
  • 1857
  • 1856
  • 1855
  • 1854
  • 1853
  • 1852
  • 1851
  • 1850
  • 1849
  • 1848
  • 1847
  • 1846
  • 1845
  • 1844
  • 1843
  • 1842
  • 1840
  • 1839
  • 1838
  • 1837
  • 1836
  • 1834
  • 1833
  • 1832
  • 1831
  • 1830
  • 1828
  • 1827
  • 1826
  • 1825
  • 1824
  • 1823
  • 1820
  • 1819
  • 1818
  • 1817
  • 1816
  • 1813
  • 1811
  • 1810
  • 1809
  • 1808
  • 1804
  • 1802
  • 1801
  • 1800
  • 1799
  • 1798
  • 1796
  • 1795
  • 1794
  • 1793
  • 1790
  • 1789
  • 1788
  • 1786
  • 1785
  • 1784
  • 1782
  • 1781
  • 1777
  • 1769
  • 1765
  • 1761
  • 1753
  • 1751
  • 1749
  • 1747
  • 1746
  • 1743
  • 1741
  • 1738
  • 1727
  • 1723
  • 1721
  • 1720
  • 1718
  • 1716
  • 1712
  • 1697
  • 1693
  • 1683
  • 1674
  • 1667
  • 1666
  • 1665
  • 1664
  • 1663
  • 1658
  • 1656
  • 1647
  • 1636
  • 1634
  • 1629
  • 1621
  • 1603
  • 1580
  • 1521
  • 1510
  • 1403
  • 1377
  • 1370
  • 1363
  • 1348
  • 1346
  • 1322
  • 1285
  • 1202
  • 1200
  • 1179
  • 1100
  • 1050
  • 541
  • 470
  • 1
Subscribe to E-History

Subscribe

* indicates required

LifeScienceHistory.com

LifeScienceHistory.com Where history is made daily, is a comprehensive companion of life science. Simply put, we dig history and we mine data.

More

  • About
  • Life Science Heroes

Advertising

  • Life Science Banner Advertising
  • Advertise Your Life Science Jobs

Legal

  • Privacy Policy
  • Terms of Use

© 2025 LifeScienceHistory.com by James Web Design

Facebook Instagram Linkedin
  • Home
  • Directory
    • General Company Directory
    • CRO Directory
    • CMO Directory
    • Genealogy on Demand
  • Careers
    • Find Your Job
    • Advertise Your Life Science Jobs
  • News and History
  • Cartoons
  • Small World
  • Earth is a Rock
    • Earth is a Rock
    • Earth is a Rock Lyrics
    • Earth is a Rock Lyrics Defined
Search